問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

National Taiwan University Hospital

List

3103Cases

2020-12-26 - 2022-06-30

Phase II

A Phase II, Prospective, Double-blinded, Multi-Centered, Multi-Regional Study to Evaluate the Safety, Tolerability and Immunogenicity of the SARS-CoV-2 vaccine candidate MVC-COV1901

  • Condition/Disease

    COVID-19

  • Test Drug

    MVC-COV1901 vaccine

Participate Sites
11Sites

Not yet recruiting7Sites

Recruiting1Sites

Terminated3Sites

2020-09-01 - 2022-01-31

Phase I

A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901

  • Condition/Disease

    COVID-19

  • Test Drug

    MVC-COV1901 vaccine (暫定)

Participate Sites
1Sites

Terminated1Sites

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2018-09-01 - 2022-12-31

Phase II

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

  • Condition/Disease

    Hepatocellular Carcinoma (HCC)

  • Test Drug

    nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞

Participate Sites
9Sites

Recruiting8Sites

2013-12-01 - 2016-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2019-07-01 - 2021-12-23

Phase III

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

  • Condition/Disease

    Primary Breast Cancer

  • Test Drug

    Ibrance

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2019-06-01 - 2021-06-11

Phase II

Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane

  • Condition/Disease

    HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer

  • Test Drug

    Tesetaxel

Participate Sites
4Sites

Terminated4Sites

2007-05-01 - 2009-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2009-03-01 - 2010-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

1 223 224 225 226 227 311
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB